海正药业（600267）公告，公司计划以不低于5000万元、不超过1亿元资金回购股份，回购价格不超过 13元/股。本次回购股份将全部用于实施员工持股计划，预计回购股份数量为384.62万股至769.23万股， 占公司总股本的0.32%-0.64%。回购期限为董事会审议通过之日起12个月内，资金来源为公司自有资 金。回购旨在完善长效激励机制，增强投资者信心，促进公司长远发展。公司将在回购期限内根据市场 情况择机实施，并根据进展情况及时履行信息披露义务。 ...

Core Points - The company announced a cash dividend of 0.21 CNY per share for the fiscal year 2024, approved at the annual shareholders' meeting on April 18, 2025 [2][4] - The total cash dividend distribution amounts to approximately 245.42 million CNY, based on a total share count of 1,198,848,196 shares, excluding 30,176,300 shares held in the company's repurchase account [4][7] - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the day before the dividend record date [3][4] Dividend Distribution Details - The cash dividend distribution is based on a total of 1,168,671,896 shares eligible for the dividend, resulting in a distribution of 2.10 CNY for every 10 shares held [4][7] - The reference price for the ex-dividend trading will be calculated using the formula: (previous closing price - cash dividend) [5][7] - The company will directly distribute cash dividends to specific shareholders, including Zhejiang Haizheng Group Co., Ltd. and others [8] Taxation Information - Individual shareholders holding unrestricted shares for over one year will not be subject to personal income tax on the dividend, while those holding for less than one year will have the tax calculated based on their holding period [9][10] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.189 CNY per share [11][12] - Other institutional investors are responsible for their own tax payments, with the gross cash dividend being 0.21 CNY per share [12]

北京康达（杭州）律师事务所 BEIJING KANGDA（HANGZHOU）LAW FIRM 杭州市上城区西子国际中心 2 号楼 1501-1503 室 邮编：310020 电话/Tel.:0571-85779929 传真/Fax:0571-85779955 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京康达（杭州）律师事务所 关于浙江海正药业股份有限公司 差异化分红事项之 专项法律意见书 康达（杭州）法意字【2025】第 0003 号 二〇二五年五月 北京康达（杭州）律师事务所 关于浙江海正药业股份有限公司 差异化分红事项之专项法律意见书 本所律师依据本法律意见书出具之日以前已经发生或存在的事实，并基于本 所律师对有关事实的了解和对中国现行有效的有关法律、行政法规和规范性文件 的理解发表法律意见。 本所律师出具本法律意见书，是基于公司及相关主体向本所承诺，其提供的 全部资料、文件及所作陈述与说明均是真实、准确、完整的；不存在虚假记载、 误导性陈 ...

浙江海正药业股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.21元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/5/15 | － | 2025/5/16 | 2025/5/16 | 差异化分红送转：是 证券代码：600267 证券简称：海正药业 公告编号：临 2025-28 号 （1）差异化分红方案 根据公司 2024 年年度股东大会通过的方案，以公司总股本 1,198,848,196 股扣 除公司回购专用证券账户股份 30,176,300 股为基数，参与本次权益分派的股份数 量为 1,168,671,896 股，向全体股东每 10 股派发现金 2.10 元（含税），合计派发现 金红利 245,421,098.16 元（含税）。2024 年度不送股、不实施资本公积金转增股本。 一、 通过分配方 ...

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has received approval for Fenbendazole oral suspension veterinary drug, enhancing its product line and market competitiveness in the veterinary sector [1][3]. Group 1: Approval Information - The product name is Fenbendazole oral suspension with an approval number of Veterinary Drug No. 110807959, valid from April 25, 2025, to April 24, 2030 [1]. - The product is developed in collaboration with 12 companies and is the first approved new veterinary drug of its kind [1]. - Fenbendazole is a benzimidazole anthelmintic used to treat infections in pigs caused by roundworms, esophageal worms, and whipworms [1]. Group 2: Product Development Timeline - The application for the veterinary drug approval was submitted by Haizheng Animal Health Co., Ltd. on January 11, 2025 [1]. Group 3: Market Position and Strategy - The approval of Fenbendazole oral suspension will enrich the company's veterinary drug product line and structure, aiding in the strategic layout of the veterinary drug sector [3].

证券代码：600267 证券简称：海正药业 公告编号：临 2025-27 号 芬苯达唑内服混悬液是海正动保公司等 12 家公司共同研制的首家获批的五 类新兽药。芬苯达唑属苯并咪唑类驱虫药，适用于治疗猪蛔虫（成虫前幼虫及成 虫）、食道口线虫（成虫）和鞭虫（成虫）感染。 2025 年 1 月 11 日，中华人民共和国农业农村部受理了海正动保公司递交的 芬苯达唑内服混悬液兽药产品批准文号申请。 浙江海正药业股份有限公司 关于子公司获得兽药产品批准文号批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）控股子公司浙江海 正动物保健品有限公司（以下简称"海正动保公司"）收到中华人民共和国农业 农村部核准签发的芬苯达唑内服混悬液兽药产品批准文号批件。现就相关情况公 告如下： 一、批件基本信息 通用名称：芬苯达唑内服混悬液 兽药产品批准文号：兽药字 110807959 批准文号有效期：2025-04-25 至 2030-04-24 商品名称：舒求肥 含量规格：20% 企业名称：浙江海 ...

Core Viewpoint - Zhejiang Hai Zheng Animal Health Products Co., Ltd., a subsidiary of Hai Zheng Pharmaceutical (600267), has received approval from the Ministry of Agriculture and Rural Affairs for its fenbendazole oral suspension veterinary drug, which will enhance the company's product line and market competitiveness in the veterinary medicine sector [1] Group 1 - The approved product is classified as a Category V new veterinary drug, effective from April 25, 2025, to April 24, 2030 [1] - The drug is intended for the treatment of infections caused by pig roundworms, esophageal worms, and whipworms [1] - The application for the approval was submitted on January 11, 2025, indicating a proactive approach by the company in expanding its veterinary product offerings [1]

Group 1 - The core viewpoint of the news indicates that the Artemisinin concept sector experienced a decline of 0.81%, ranking among the top declines in the concept sector [1] - Within the Artemisinin concept sector, major companies such as Kunming Pharmaceutical Group, New Harmony, and Rundu Co., Ltd. saw significant declines, while companies like Baihua Pharmaceutical, China Resources Sanjiu, and Zhejiang Medicine recorded gains of 1.21%, 0.75%, and 0.75% respectively [1] Group 2 - The financial data shows that the Artemisinin concept sector had a net outflow of 96 million yuan, with eight stocks experiencing net outflows, led by Kunming Pharmaceutical Group with a net outflow of 62.05 million yuan [2] - Other companies with notable net outflows include Rundu Co., Ltd. with 11.84 million yuan, Fosun Pharmaceutical with 9.02 million yuan, and Zhejiang Medicine with 6.48 million yuan [2] - Conversely, the stocks with the highest net inflows included Baihua Pharmaceutical and New Harmony, with net inflows of 6.07 million yuan and 1.19 million yuan respectively [2]

Core Viewpoint - The rise and fall of the ASUS Eee PC, which pioneered the netbook category, illustrates the rapid evolution of consumer electronics and the impact of market dynamics on product lifecycle [1][13][43] Group 1: Product Launch and Market Impact - ASUS became the world's second-largest OEM in 2006, primarily manufacturing computers and servers for Dell and HP [1] - The launch of the ASUS Eee PC in 2007 marked the beginning of the netbook revolution, achieving nearly 40 million units sold at its peak [1][9] - The Eee PC was priced at $299, significantly lower than traditional laptops, which contributed to its rapid adoption [4][9] Group 2: Market Dynamics and Consumer Behavior - The global financial crisis in 2007 amplified the appeal of low-cost netbooks as consumers sought affordable alternatives to traditional laptops [7][9] - The entry of various manufacturers, including Acer and numerous low-cost producers in Shenzhen, further drove down prices and expanded the netbook market [6][9] - Netbooks found a niche in the education sector, particularly in developing countries, where they were seen as a cost-effective solution for providing students with computers [9][12] Group 3: Decline and Technological Evolution - Despite initial success, netbook sales began to decline sharply after 2010, with sales dropping from 39.4 million units in 2010 to just 1.4 million by 2013 [10][13] - The emergence of tablets and smartphones, which offered better performance and portability, contributed to the decline of netbooks [30][36] - The rapid advancement of technology, as described by Moore's Law, led to increased performance in traditional laptops, making them more competitive against netbooks [26][29] Group 4: Legacy and Industry Influence - The netbook phenomenon highlighted consumer demand for lightweight, affordable computing solutions, influencing the design and marketing of future products like ultrabooks and Chromebooks [42][43] - Although netbooks were short-lived, their impact on the industry was significant, prompting manufacturers to explore new market segments and innovate in product design [42][43]

Core Viewpoint - Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its drug, Dihydrosulfonyladenosine Methionine Enteric-Coated Tablets, which has passed the consistency evaluation for generic drug quality and efficacy [1][2]. Group 1: Drug Information - The drug is named Dihydrosulfonyladenosine Methionine Enteric-Coated Tablets, in tablet form, with a specification of 0.5g [1]. - The original product was developed by Abbott, and the main domestic manufacturers include Hai Zheng Pharmaceutical and Zhejiang Prolong Pharmaceutical Co., Ltd. [2]. - The global sales of Dihydrosulfonyladenosine Methionine Enteric-Coated Tablets are projected to be approximately $17.04 million in 2024, with domestic sales around $3.84 million [2]. Group 2: Financial Investment - The company anticipates a sales revenue of approximately 145 million RMB for the Dihydrosulfonyladenosine Methionine Enteric-Coated Tablets in 2024 [2]. - The company has invested about 25.23 million RMB in the consistency evaluation for this drug [2]. Group 3: Market Impact - The approval of the drug through the consistency evaluation is expected to enhance its market share and competitiveness due to increased support in medical insurance payments and procurement by medical institutions [4].